Document is current
Any future updates will be listed below
-
Authors
Rahmqvist, Ida
Dahlstrand Rudin, Agnes
Mellström, Elisabeth
R. Ibrahim, Raghda
Andersson, Daniel
Pujol Calderón, Fani
Ordqvist Redfors, Anna
Rostamzadeh, Niki
Franssila, Wilma
Karlsson, Christin
Zetterlund, Fanny
Khashan, Robert
Frostdahl, Hanna
Österlund, Tobias
Ek, Torben
Fagman, Henrik
Ståhlberg, Anders
Dalin, Martin
-
Funding
Funding for this research was provided by:
Wallenberg Centre for Molecular and Translational Medicine
The Swedish Childhood Cancer Fund (2022-0030, KP2020-0002)
The Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (ALFGBG-965065, ALFGBG-962238)
The Swedish Agency for Economic and Regional Growth (20370391, 20370391)
The Swedish Cancer Society (22-2080)
The Swedish Research Council (2021-1008)
The Sjöberg Foundation
Sweden’s Innovation Agency
Svenska Sällskapet för Medicinsk Forskning (SG-22-0226-H-01)
The Swedish Society of Medicine (SLS-935265)
The Assar Gabrielsson foundation (BGR21-07)
Västra Götalandsregionen (NHV-978551)
Region Västra Götaland (NHV-1014111)
Sahlgrenska International starting grant
Svensson’s research fund
- License Information
-
More Information
Article History
Received: 24 April 2025
Accepted: 1 October 2025
First Online: 21 October 2025
Competing interests
: The authors declare the following financial competing interests: A.S. is co-inventor of the SiMSen-Seq technology that is patent-protected (U.S. Serial No.:15/552,618). A.S. declares stock ownership in Tulebovaasta, Iscaff Pharma and SiMSen Diagnostics, and is a board member in Tulebovaasta. The authors declare no non-financial competing interests.
